Published in Medical Letter on the CDC and FDA, September 28th, 1998
Viragen uses white blood cells as the source material for the manufacture of Omniferon, a multi-subtype, highly purified natural alpha interferon drug currently in preclinical studies. The company expects to complete such studies by the end of 1998 and commence human studies in hepatitis C shortly thereafter. In addition, Viragen will also use white blood cells for the manufacture of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.